
|Videos|October 15, 2017
Who Will Benefit from the Darunavir Single-Tablet Regimen for HIV?
Author(s)Contagion® Editorial Staff
Magda Opsomer, MD, reveals who will benefit from the darunavir single-tablet HIV regimen.
Advertisement
Magda Opsomer, MD, director and clinical leader of Infectious Diseases and Vaccines at Janssen Pharmaceutical Companies, Belgium, reveals who will benefit from the darunavir single-tablet HIV regimen.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Advertisement
Advertisement
Trending on Contagion Live
1
Nearly 1 in 5 Urinary Tract Infections in Southern California Linked to Contaminated Meat
2
High Continued Adherence of Lenacapavir in Individuals Who Use Substances and Alcohol
3
Moderna Discontinues Development of Vaccine for Congenital CMV After Not Meeting Primary Efficacy Endpoint
4
Dynavax Presents Data for Shingles Vaccine, Launches Head-to-Head Study Against Shingrix
5











































































































































































































































































































